ASRS 2023 - PK and safety of sozinibercept (OPT-302)
Filed with ASX · · 12 pages · English
In the deck
Earlier from Opthea
- Opthea Receives A$8.7million R&D Tax Incentive
- Half Year Accounts
- Response to ASX Query
- Opthea Ph2b Trial Results with OPT-302 published in Journal
- Opthea Corporate Presentation - San Francisco Jan 2023
Later from Opthea
- Opthea announces A$80m Capital raise
- Opthea Investor Presentation
- Prospectus
- Opthea completes institutional offer and increases raise
- Opthea Retail Entitlement Offer Opens
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea